Fiera Capital (Canada)’s Aimmune Therapeutics AIMT Stock Holding History

Fiera Capital (Canada)’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,575,531	Closed	-$26.3M	–	664
2020 Q2	$26.3M	Sell	1,575,531 -34,579	-2%	-$587K	0.09%	138
2020 Q1	$23.2M	Sell	1,610,110 -57,016	-3%	-$1.46M	0.1%	136
2019 Q4	$55.8M	Buy	1,667,126 +427,499	+34%	+$12M	0.19%	80
2019 Q3	$26M	Buy	1,239,627 +1,086,634	+710%	+$22.2M	0.1%	149
2019 Q2	$3.19M	Sell	152,993 -7,579	-5%	-$156K	0.01%	312
2019 Q1	$3.59M	Buy	160,572 +71,519	+80%	+$1.68M	0.01%	296
2018 Q4	$2.13M	Buy	89,053 +31,686	+55%	+$820K	0.01%	385
2018 Q3	$1.56M	Sell	57,367 -35,338	-38%	-$1,000K	0.01%	448
2018 Q2	$2.49M	Buy	+92,705	New	+$2.84M	0.01%	388

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fiera Capital (Canada)'s AIMT Position: Q3 2020 in Review

Fiera Capital (Canada) sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 1,575,531 shares — an estimated $26.3M sold.

Fiera Capital (Canada) first reported a position in AIMT in Q2 2018 and held it in 9 quarters. The position peaked at $55.8M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

Fiera Capital (Canada) reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
Fiera Capital (Canada) sold 1,575,531 Aimmune Therapeutics shares in Q3 2020, an estimated $26.3M.
Fiera Capital (Canada) first reported a position in Aimmune Therapeutics in Q2 2018 and held it in 9 quarters.
Fiera Capital (Canada)'s Aimmune Therapeutics position peaked at $55.8M in Q4 2019.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Fiera Capital (Canada)'s 13F filing for Q3 2020, filed 12 Nov 2020.